AUCATZYL (obecabtagene autoleucel) — Full data
Late 2026
Longer-term follow up data from CARLYSLE trial in patients with severe refractory systemic lupus erythematosus By year-end 2026Source filing
AUTL biotech catalysts & pipeline
AUTOLUS THERAPEUTICS PLC · Data as of 2026-09-08
Upcoming catalysts
AUTO8 — Initial data
Late 2026
The Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing and initial data are expected to be reported at the end of 2026.Source filing
AUCATZYL (obecabtagene autoleucel) — Initial data
Q4 2026
The next data update from the Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (SLE) has been submitted for presentation at the American College of Rheumatology (ACR) Annual Meeting in the fourth quarter of 2026.Source filing
AUCATZYL (obecabtagene autoleucel) — Initial data
Q1 2027
Initial clinical data from BOBCAT Phase 1 trial in patients with progressive MS Q1 2027Source filing
AUCATZYL (obecabtagene autoleucel) — Topline data
H2 2027
A larger data set with longer follow up will be reported in the second half of 2027.Source filing
AUCATZYL (obecabtagene autoleucel) — Topline data
Late 2027
Phase 2 data from CATULUS trial in patients with pediatric r/r B-ALL By year-end 2027Source filing
AUCATZYL (obecabtagene autoleucel) — Topline data
in 2028
LUMINA, the pivotal Phase 2 study of obe-cel in patients with refractory lupus nephritis (LN) continues enrolling in five countries and the Company expects to report data in 2028.Source filing
AUCATZYL (obecabtagene autoleucel) — Conference presentation
Nov 6–Nov 11
Our next data update from the Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus ("SLE") has been submitted for presentation at the American College of Rheumatology ("ACR") Annual Meeting in the fourth quarter of 2026.Source filing